Skip to main content
. 2018 Jan 11;9(3):337–347. doi: 10.1111/1759-7714.12574

Figure 4.

Figure 4

Meta‐analysis of recurrence‐free survival (RFS) following stereotactic ablative radiotherapy (SABR) versus lobectomy for stage I non‐small cell lung cancer. Comparison of (a) one‐year, (b) three‐year, and (c) five‐year RFS rates of SABR and lobectomy. CI, confidence interval; OR, odds ratio.